tiprankstipranks
Psyence Biomedical Trials Psilocybin for Palliative Care
Company Announcements

Psyence Biomedical Trials Psilocybin for Palliative Care

Story Highlights

Psyence Group (TSE:PSYG) has released an update.

Don't Miss Our Christmas Offers:

Psyence Group’s associate, Psyence Biomedical, has initiated a clinical trial in Australia to study the effects of nature-derived psilocybin on Adjustment Disorder in palliative care. The Phase IIb study will be supported by partnerships with Fluence and iNGENū CRO Pty Ltd, and marks progress in exploring psilocybin’s potential for treating mental health conditions.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Sells Stake to Psyence Biomedical
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Expands Psilocybin Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App